IPO
Estimated total sales of HEMOBLAST™ Bellows for the first nine months of 2019 are expected to show strong growth at €2.5 million (compared to €1.5 million for the first half of 2019 and €0.6 million for the full year 2018) and are expected to be on track to achieve the 2019 revenue guidance range of €4.0-€4.5 million
Amryt, a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases, announces interim results for the six months ended 30 June 2019.
Motif Bio plc announced unaudited financial results for the half year ended June 30, 2019 and reported on its progress year to date.
Creoptix AG announced that is has raised CHF 8 million in the first closing as part of a Series C financing round.
Arctoris Ltd, a fully automated drug discovery platform for virtual and traditional biotechnology companies, pharmaceutical corporations and academia, announced that it has successfully closed a seed funding round of £3.2 million to advance its novel drug discovery offering.
Novo Seeds, the company creation team of Novo Holdings, announced that it has co-led the €20 million Series A financing round in STipe Therapeutics (STipe).
Synairgen plc, the respiratory drug discovery and development company, announces its unaudited interim results for the six months ended 30 June 2019.
Centauri Therapeutics, an immunotherapy company active in oncology and infectious diseases, announces that it will attend the following scientific and investor conferences
Beam, which is one of BioSpace’s NextGen Bio “Class of 2019” Life Science Startups to Watch in 2019, filed its IPO plans with the U.S. Securities and Exchange Commission on Friday.
T3 Pharmaceuticals AG, a Basel-based company focusing on immuno-oncology, closes its second financing round of over 12M CHF with existing investors joined by Boehringer Ingelheim Venture Fund and Reference Capital SA.
PRESS RELEASES